NCT06300203View on ClinicalTrials.gov

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Seasonal Allergic Rhinitis
Interventions
BIOLOGICAL

Interleukin-4 receptor responders

Interleukin-4 receptor was injected subcutaneously.

OTHER

Placebo

Placebo was injected subcutaneously.

Trial Locations (1)

100000

RECRUITING

Beijing Tongren Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER